Cinoxacin (Cinobac; Compound 64716)

Description: Cinoxacin (Cinobac; Compound 64716) was a synthetic antimicrobial agent for oral administration. It belongs to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid. It was commonly used thirty years ago to treat urinary tract infections in adults. There are reports that cinoxacin had also been used to treat initial and recurrent urinary tract infections and bacterial prostatitis in dogs however this veterinary use was never approved by the FDA. In complicated UTI, the older gyrase-inhibitors such as cinoxacin are no longer indicated. It has been discontinued in the U.K. as well the United States, both as a branded drug or a generic. The marketing authorization of cinoxacin has been suspended throughout the EU.

References: Cinoxacin:mechanism of action, spectrum of activity, pharmacokinetics, adversereactions, and therapeutic indications. Pharmacotherapy. 1982Sep-Oct; 2(5):266-72.; Quercia O, Rafanelli S, Emiliani F, Stefanini GF. Anaphylactic reaction tocinoxacin: report of one case associated with inferior acute myocardialinfarction. Eur Ann Allergy Clin Immunol. 2003 Feb; 35(2):61-3. PubMed PMID:12674041.